Auxogyn Announces First European Patent For Eeva Test

Auxogyn Announces First European Patent For Eeva Test
MENLO PARK, CA — January 3, 2013 – Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that the European Patent Office has issued a notice of intention to grant a patent to Stanford University that will cover certain predictive parameters for the assessment of embryo viability during in vitro fertilization (IVF) procedures used in Auxogyn’s Early Embryo Viability Assessment (Eeva) Test. In addition, the U.S. Patent and Trademark Office (USPTO) has issued a third U.S. patent that also covers predictive parameters used in the assessment of embryo viability during IVF procedures. Auxogyn is the exclusive licensee of both patents.

“We are thrilled with the European Patent Office’s decision to issue this patent,” said Lissa Goldenstein, president and chief executive officer of Auxogyn. “This European patent provides further validation that bodies governing intellectual property worldwide recognize the inventive work done at Stanford University in the field of human embryology. Our intellectual property will play an important role as Auxogyn continues to innovate in the field of reproductive health with the goal of making a difference in the lives of families around the world.”

Goldenstein added, “The value of the Eeva technology lies in its unique ability to evaluate and predict embryo viability as early as day 3. By providing this valuable insight into early embryo development, IVF clinicians now have access to critical information about the embryo that they didn’t have before. This information can be essential in determining which embryo to transfer or freeze, ultimately helping improve the odds for success.”